NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology
Ana I. Rojo(Biomedical Research Networking Center on Neurodegenerative Diseases), Antonio Cuadrado(Biomedical Research Networking Center on Neurodegenerative Diseases), Elena M. Ribé(Warneford Hospital), Marta Pajares(Instituto de Salud Carlos III), Alejo Nevado‐Holgado(University of Oxford), Patricia Rada(Consejo Superior de Investigaciones Científicas), Richard Killik(King's College London), Masayuki Yamamoto(Tohoku University), Simon Lovestone(Royal Buckinghamshire Hospital), Fred Van Leuven(KU Leuven), Ángel Núñez(Universidad Autónoma de Madrid)
Cited by 216
Related Papers
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease
|Nature Genetics|2009|3.4k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease
|Nature Genetics|2011|2.1k
Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
|Nature Communications|2016|1.8k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k